The largest database of trusted experimental protocols

D0564 1mg

Manufactured by Merck Group
Sourced in United States

D0564-1MG is a laboratory reagent supplied by Merck Group. It is a chemical compound used in research and scientific applications. The core function of this product is to serve as a substrate or component in various laboratory experiments and analyses. No further details on the intended use or application are provided.

Automatically generated - may contain errors

2 protocols using d0564 1mg

1

Liver Damage Assessment in Alb-TRECK/SCID Mice

Check if the same lab product or an alternative is used in the 5 most similar protocols
Alb-TRECK/SCID mice were provided by our collaborators at the Tokyo Metropolitan Institute of Medical Science. Homozygosity was confirmed by backcrossing for at least three generations. Alb-TRECK/SCID mice were housed at Yokohama City University. Animal experimental work was conducted in accordance with the Guidelines for Proper Conduct of Animal Experiments (Science Council of Japan), and all experimental procedures were approved by the institutional review board of the Animal Research Center, Yokohama City University School of Medicine (No.075).
DT (Sigma, St Louis, MO, USA; D0564-1MG) was intraperitoneally administered (1.5 μg/kg) to 8-week-old Alb-TRECK/SCID mice, and the degree of liver damage was assessed by serum aspartate aminotransferase (AST) activity levels.
+ Open protocol
+ Expand
2

Depletion and Blockade Strategies for Studying Immune Cell Roles

Check if the same lab product or an alternative is used in the 5 most similar protocols
For DT-mediated depletion of KCs, Clec4fcreRosa26LSL-DTR mice and Rosa26LSL-DTR mice were intraperitoneally injected with 100 ng DT (D0564-1MG, Sigma-Aldrich) as a single dose or weekly injections25 (link), as indicated in the figure legends for the corresponding experiments. The efficiency of KC depletion was determined in Extended Data Fig. 1j.
For CSF1R inhibitor treatment with PLX562231 , C57BL/6J mice were fed ad libitum with PLX5622-impregnated chow (1,200 mg per kg, provided by Plexxicon) or control chow 2 weeks before injection of tumour cells.
For the SIRPA blockage assay, Clec4fcreId3f/f mice and Id3f/f littermates were intraperitoneally injected with control IgG (HRPN, BioXcell) or 250 μg anti-SIRPA (P84, BioXcell) 2 days before and every 2 days after tumour cell injection.
For phosphatidylserine blockade80 (link), C57BL/6J mice were injected i.v. with PBS or 1 μg MFG-E8(D89E)81 (link) (gift from S. Nagata), 6 h before injection of tumour cells.
For NK cell and CD8 T cell depletion, 8–12-week-old Clec4fcreId3f/f mice and Id3f/f littermates were intraperitoneally injected with control IgG (HRPN, BioXcell), or 200 μg anti-NK1.1 (BE0036, BioXcell) and 200 μg anti-CD8 (BP0061, BioXcell) 1 day before tumour injection and every 4 days afterwards.
+ Open protocol
+ Expand

About PubCompare

Our mission is to provide scientists with the largest repository of trustworthy protocols and intelligent analytical tools, thereby offering them extensive information to design robust protocols aimed at minimizing the risk of failures.

We believe that the most crucial aspect is to grant scientists access to a wide range of reliable sources and new useful tools that surpass human capabilities.

However, we trust in allowing scientists to determine how to construct their own protocols based on this information, as they are the experts in their field.

Ready to get started?

Sign up for free.
Registration takes 20 seconds.
Available from any computer
No download required

Sign up now

Revolutionizing how scientists
search and build protocols!